This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Green, B. A. Articles by Zlotnick, G. W. Search for Related Content PubMed PubMed Citation Articles by Green, B. A. Articles by Zlotnick, G. W.

 Previous Article  |  Next Article 

Infection and Immunity, July 2005, p. 4454-4457, Vol. 73, No. 7
0019-9567/05/$08.00+0     doi:10.1128/IAI.73.7.4454-4457.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Certain Site-Directed, Nonenzymatically Active Mutants of the Haemophilus influenzae P4 Lipoprotein Are Able To Elicit Bactericidal Antibodies

Bruce A. Green,^1* Elizabeth Baranyi,¹ Thomas J. Reilly,^2, Arnold L. Smith,^2, and Gary W. Zlotnick¹

Wyeth Vaccines Discovery Research, 401 N. Middletown Rd., Pearl River, New York 10965,¹ Department of Molecular Microbiology and Immunology, University of Missouri Medical School, Columbia, Missouri 65212²

Received 15 December 2004/ Returned for modification 25 January 2005/ Accepted 21 February 2005

The Haemophilus influenzae P4 lipoprotein (hel) is a potential component of a nontypeable H. influenzae otitis media vaccine. Since P4 is known to be an enzyme, nonenzymatically active forms of recombinant P4 are required. After site-directed mutagenesis of the hel gene, three of the mutated proteins were shown to be vaccine candidates.

Editor: J. N. Weiser

Present address: Department of Pathobiology, College of Veterinary Medicine, University of Missouri, Columbia, MO 65212.

Present address: Seattle Biomedical Research Institute, 307 Westlake Avenue, Suite 500, Seattle, WA 98109.